SOLENO THERAPEUT. DL-001 (6XC) - Total Assets
Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) holds total assets worth €563.83 Million EUR (≈ $659.18 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SOLENO THERAPEUT. DL-001 - Total Assets Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's total assets have evolved over time, based on quarterly financial data. Also see 6XC company net worth for the company's overall valuation and market capitalisation.
SOLENO THERAPEUT. DL-001 - Asset Composition Analysis
Current Asset Composition (December 2025)
SOLENO THERAPEUT. DL-001's total assets of €563.83 Million consist of 63.1% current assets and 36.9% non-current assets. Review total liabilities of SOLENO THERAPEUT. DL-001 to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €28.21 Million | 5.0% |
| Inventory | €15.02 Million | 2.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.86 Million | 0.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SOLENO THERAPEUT. DL-001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SOLENO THERAPEUT. DL-001 (6XC) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SOLENO THERAPEUT. DL-001's current assets represent 63.1% of total assets in 2025, an increase from 63.1% in 2021.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, down from 59.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 35.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 5.0% of total assets.
SOLENO THERAPEUT. DL-001 Competitors by Total Assets
Key competitors of SOLENO THERAPEUT. DL-001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
SOLENO THERAPEUT. DL-001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.80 | 15.68 | 17.26 |
| Quick Ratio | 5.55 | 15.68 | 17.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €294.45 Million | €275.14 Million | €243.24 Million |
SOLENO THERAPEUT. DL-001 - Advanced Valuation Insights
This section examines the relationship between SOLENO THERAPEUT. DL-001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.57 |
| Latest Market Cap to Assets Ratio | 4.09 |
| Asset Growth Rate (YoY) | 70.4% |
| Total Assets | €563.83 Million |
| Market Capitalization | $2.31 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values SOLENO THERAPEUT. DL-001's assets at a significant premium (4.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: SOLENO THERAPEUT. DL-001's assets grew by 70.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual total assets of SOLENO THERAPEUT. DL-001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €563.83 Million ≈ $659.18 Million |
+70.36% |
| 2024-12-31 | €330.97 Million ≈ $386.94 Million |
+83.17% |
| 2023-12-31 | €180.69 Million ≈ $211.25 Million |
+581.93% |
| 2022-12-31 | €26.50 Million ≈ $30.98 Million |
-25.47% |
| 2021-12-31 | €35.55 Million ≈ $41.57 Million |
-- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more